BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/5/2025 11:28:01 AM | Browse: 1 | Download: 0
 |
Received |
|
2025-06-03 16:02 |
|
Peer-Review Started |
|
2025-06-03 16:02 |
|
First Decision by Editorial Office Director |
|
2025-06-19 09:12 |
|
Return for Revision |
|
2025-06-19 09:12 |
|
Revised |
|
2025-07-01 14:30 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-09-05 02:40 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-09-05 08:25 |
|
Articles in Press |
|
2025-09-05 08:25 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-11-25 05:16 |
|
Publish the Manuscript Online |
|
2025-12-05 11:28 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Michael Colwill, Jessica Padley, Umang Qazi, Sonia Mehta, Fiona Donovan, Ana Margarida Alves, Richard Pollok, Kamal Patel, Patrick Dawson, Sailish Honap and Andrew Poullis |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Michael Colwill, MRCP, Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, Blackshaw Road, London SW17 0QT, London, United Kingdom. michael.colwill@stgeorges.nhs.uk |
| Key Words |
Crohn's disease; Risankizumab; Ustekinumab; Advanced therapy |
| Core Tip |
Despite evidence of superiority of risankizumab over ustekinumab when managing Crohn’s disease, it is unknown if switching from ustekinumab to risankizumab is effective. This retrospective study evaluated outcomes in 51 adults who switched from ustekinumab to risankizumab. Significant reductions in Harvey-Bradshaw Index scores were observed at all timepoints, with remission rates rising from 37.1% to 94.4% over 9 months. Albumin, C-reactive protein and calprotectin also improved. Patients with secondary loss of response to ustekinumab responded better than primary non-responders. No serious adverse events occurred. These findings support risankizumab as a safe, effective option after ustekinumab failure in refractory Crohn’s. |
| Publish Date |
2025-12-05 11:28 |
| Citation |
Colwill M, Padley J, Qazi U, Mehta S, Donovan F, Alves AM, Pollok R, Patel K, Dawson P, Honap S, Poullis A. Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center. World J Gastrointest Pharmacol Ther 2025; 16(4): 110273 |
| URL |
https://www.wjgnet.com/2150-5349/full/v16/i4/110273.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v16.i4.110273 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
